Navigant’s Pathogen Inactivation System Will Compete On Price, Ease Of Use
This article was originally published in The Gray Sheet
Executive Summary
Navigant Biotechnologies CEO Teresa Ayers' first priority as head of the Gambro subsidiary will be to raise funds to commercialize its blood pathogen reduction technology